Epilepsy

The division director of epilepsy and associate professor of neurology at The Ohio State University Wexner Medical Center talked about the impact of ongoing seizures in patients with drug-resistant epilepsy and the importance of education for emerging opportunities in epilepsy care. [WATCH TIME: 3 minutes]

Clobazam and valproate, when used concomitantly, produced a greater treatment effect with ganaxolone than other antseizure medications levetiracetam and vigabatrin.

Notably, nearly 50% of patients prescribed the Biocodex therapy were not on concomitant clobazam, a contrasting practice with the FDA label’s indication. To date, no data support its use as monotherapy for Dravet syndrome.

The retrospective cohort study, led by R. Eugene Ramsay, MD, highlighted the impacts of vigabatrin in patients with super refractory status epilepticus.

The division chief of pediatric neurosurgery at Ann & Robert H. Lurie Children's Hospital of Chicago talked about findings from a recently published study on long-term survival of pediatric patients with drug-resistant epilepsy which was presented at AES 2023. [WATCH TIME: 6 minutes]

Using a caregiver questionnaire, noted improvements in verbal, non-verbal communication, and engagement were observed on soticlestat treatment.

Here's some of what is coming soon to NeurologyLive® this week.

The vice president of medical affairs at SK Life Science discussed how epilepsy remains a formidable challenge in the development of effective therapies to achieve seizure freedom. [WATCH TIME: 5 minutes]

A recent 6-month cohort study presented at the 2023 AES Annual Meeting demonstrated that adjuvant cenobamate significantly reduced seizures in patients with severe refractory focal epilepsy and suggested potential benefits in hospitalization rates.

The professor of neurology at Johns Hopkins University School of Medicine discussed the traditional view of epilepsy treatment and how the paradigm has shifted to provide new treatments to achieve seizure freedom for drug-resistant patients. [WATCH TIME: 5 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Epilepsy Society.

In a recent post hoc analysis of the Study C021 trial, findings support the idea that early adjustments to concomitant antiseizure medications enhance the retention of cenobamate, an FDA-approved treatment for focal seizures.

The professor of neurology in the department of neuroscience at Monash University discussed implementation strategies for treatment approaches to achieve seizure freedom in patients with epilepsy. [WATCH TIME: 5 minutes]

Over a 12-week trial period, Asian patients treated with brivaracetam demonstrated efficacy and safety outcomes that were similar to other populations previously observed.

Neurology News Network for the week ending December 1, 2023. [WATCH TIME: 4 minutes]

In an analysis of lacosamide in pregnant women, a low number of preterm birth deliveries were reported, with no new safety concerns identified.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 1, 2023.

The director of the Mid-Atlantic Epilepsy & Sleep Center and adjunct associate professor of neurology at George Washington University discussed the advancements in epilepsy research, especially for drug-resistant epilepsy, to be presented at AES 2023. [WATCH TIME: 4 minutes]

Both pediatric and adult patients with tuberous sclerosis complex demonstrated significant reductions in TSC-associated seizures with no new safety concerns identified.

The division director of epilepsy and associate professor of neurology at The Ohio State University Wexner Medical Center discussed the profound repercussion of ongoing seizures for patients with epilepsy which is to be presented at AES 2023 in SK Life Science’s symposium. [WATCH TIME: 5 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with William Gallentine, DO. [LISTEN TIME: 17 minutes]

According to a recent cross-sectional study on pediatric patients with epilepsy in Western China, most patients’ caregivers had treatment access barriers, especially for making appointments, obtaining diagnosis and examination results, and having a response from the care team.

In a new announcement, the FDA warns patients to immediately seek out medical attention if unexplained rash, fever, or swollen lymph nodes develop when using the antiseizure medications levetiracetam and clobazam.

As part of our monthly clinician spotlight, NeurologyLive® highlighted epilepsy expert Patricia C. Dugan, MD, director of the epilepsy fellowship program at NYU Langone Health.

The interim chief of pediatric neurology at Stanford Medicine Children’s Health discussed progress in preventing seizures among patients with epilepsy, the potential for gene-targeted therapies, and the importance of localizing where seizures are coming from. [WATCH TIME: 5 minutes]